JO
KTTA icon

John Overdeck’s Pasithea Therapeutics KTTA Stock Holding History

John Overdeck’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.1K Buy
64,166
+43,112
+205% +$29.7K ﹤0.01% 4964
2026
Q1 		$15.6K Sell
21,054
-27,719
-57% -$23.2K ﹤0.01% 4518
2025
Q4 		$62.9K Buy
48,773
+13,013
+36% +$11.4K ﹤0.01% 3911
2025
Q3 		$26.2K Buy
+35,760
New +$26.1K ﹤0.01% 3583

Other funds holding KTTA

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

John Overdeck's KTTA Position: Q2 2026 in Review

John Overdeck increased its Pasithea Therapeutics (KTTA) stake by 205% in Q2 2026, buying an estimated $29.7K and bringing the position to 64,166 shares worth $33.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4964.

John Overdeck first reported a position in KTTA in Q3 2025 and has held it in 4 quarters since. The position peaked at $62.9K in Q4 2025. 25 funds tracked by Wall St. Rank hold KTTA as of Q2 2026.

  • John Overdeck held 64,166 shares of Pasithea Therapeutics worth $33.1K as of Q2 2026.
  • John Overdeck bought 43,112 Pasithea Therapeutics shares in Q2 2026, an estimated $29.7K.
  • Pasithea Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4964 holding.
  • John Overdeck first reported a position in Pasithea Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • John Overdeck's Pasithea Therapeutics position peaked at $62.9K in Q4 2025.
  • 25 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.